Associated tags: Intelligence, Patient, Hospital, Health, Cardiology, Medical Devices, Pharmaceutical industry, Software, Research, Medical device, Practice Management, Science, Health Technology, Teaching, MD, Heart, Data Management
Locations: ALISO VIEJO, UNITED STATES, NORTH AMERICA, CALIFORNIA, US
Research,
Technology,
Medical Devices,
Health Technology,
Cardiology,
Software,
Health,
Data Management,
Science,
Artificial Intelligence,
Aortic stenosis,
Aortic regurgitation,
Patient,
Mortality,
MD,
American College,
TAVR,
Multimedia,
Teaching egnite, Inc. , a leading digital health company for cardiovascular care, and JenaValve Technology, Inc. , a developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, unveil a novel study presented at the American College of Cardiology’s Annual Scientific Session & Expo (ACC.24).
Key Points:
- egnite, Inc. , a leading digital health company for cardiovascular care, and JenaValve Technology, Inc. , a developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, unveil a novel study presented at the American College of Cardiology’s Annual Scientific Session & Expo (ACC.24).
- This press release features multimedia.
- “This research underscores the poor outcomes for patients with moderate AR who exhibit cardiac damage, stressing the need to monitor distinct characteristics in this population.
- Recent conservative estimates suggest that over 500,000 patients in the United States are diagnosed with moderate or severe AR, indicating a substantial opportunity for novel therapeutic options to treat patients suffering from AR.
Technology,
Medical Devices,
Health Technology,
Cardiology,
Software,
Practice Management,
Managed Care,
Health,
Artificial Intelligence,
Bernard Marcus,
International Society,
Coronary artery disease,
Partnership,
George Washington University,
Patient,
Research,
Cardiac catheterization,
NYU,
Treasurer,
MD,
Society,
Amoroso,
Medical school,
Vinod,
Physician,
Pharmaceutical industry egnite, Inc. , a leading digital health company specializing in cardiovascular care, today announced the addition of two distinguished physicians, Vinod H. Thourani, MD and Nicholas Amoroso, MD, to its Medical Advisory Board .
Key Points:
- egnite, Inc. , a leading digital health company specializing in cardiovascular care, today announced the addition of two distinguished physicians, Vinod H. Thourani, MD and Nicholas Amoroso, MD, to its Medical Advisory Board .
- His involvement in novel clinical trials and contributions to leading cardiology research brings a wealth of experience to egnite’s medical advisory board.
- "We are honored to welcome Vinod and Nick to egnite’s Medical Advisory Board," said Joel Portice, president and CEO of egnite.
- The appointment of Thourani and Amoroso to its Medical Advisory Board underscores egnite’s commitment to excellence and advancement in developing solutions to address the evolving needs of cardiovascular patients and providers.
Cardiology,
Software,
Practice Management,
Health,
Artificial Intelligence,
Medical Devices,
Health Technology,
Technology,
Disease,
Intelligence,
Risk,
Artificial intelligence,
Patient,
Stroke,
Mortality,
Death,
A.I,
Heart failure,
Cardiovascular disease,
Trailblazer,
Physician,
Pharmaceutical industry Fast Company, the world’s leading progressive business media brand, announced egnite, Inc. as one of the World’s Most Innovative Companies in their 2024 ranking.
Key Points:
- Fast Company, the world’s leading progressive business media brand, announced egnite, Inc. as one of the World’s Most Innovative Companies in their 2024 ranking.
- egnite, a leading digital health company specializing in artificial intelligence solutions to advance cardiovascular care, stands at the forefront of innovation in the healthcare sector.
- The 2024 list showcases businesses pioneering advancements within their industries, setting new standards for innovation and paving the way for future breakthroughs.
- As the company continues to leverage its technology to help improve patient care, it remains dedicated to shaping the future of cardiovascular health.
Retrieved on:
Thursday, October 26, 2023
Cardiology,
Biometrics,
Biotechnology,
Pharmaceutical,
Oncology,
General Health,
Health,
Clinical Trials,
Patient,
Associate,
Sharma,
MR,
Mortality,
MBBS,
Research,
Teaching,
TCT,
Mitral regurgitation,
Pharmaceutical industry,
Nursing,
Medical imaging,
FRACP egnite, Inc. , a leading cardiovascular digital health company, announced today that novel research on mitral regurgitation (MR) was presented by cardiologist Rahul Sharma, MBBS, FRACP, at the Transcatheter Cardiovascular Therapeutics (TCT) conference.
Key Points:
- egnite, Inc. , a leading cardiovascular digital health company, announced today that novel research on mitral regurgitation (MR) was presented by cardiologist Rahul Sharma, MBBS, FRACP, at the Transcatheter Cardiovascular Therapeutics (TCT) conference.
- These findings unveiled critical insights into treatment patterns and associated outcomes in patients with MR.
- The implications of delayed treatment, particularly in moderate-to-severe MR, cannot be overstated, as it may lead to poor patient outcomes."
- This research represents one of the largest real-world analyses of treatment patterns and associated outcomes for patients with MR and highlights the importance of timely intervention.
Retrieved on:
Wednesday, October 25, 2023
Health,
Hospitals,
Surgery,
Health Technology,
Research,
Science,
Cardiology,
Patient,
American College,
AVR,
Aortic stenosis,
MD,
JACC,
Journal,
Disease,
Teaching,
TCT,
Pharmaceutical industry,
Nursing egnite, Inc. , a leading cardiovascular digital health company, announced today that novel research on aortic stenosis (AS) was presented by cardiologist Philippe Généreux, MD, Director of the Structural Heart Program of Morristown’s Gagnon Cardiovascular Institute, at the Transcatheter Cardiovascular Therapeutics (TCT) conference.
Key Points:
- egnite, Inc. , a leading cardiovascular digital health company, announced today that novel research on aortic stenosis (AS) was presented by cardiologist Philippe Généreux, MD, Director of the Structural Heart Program of Morristown’s Gagnon Cardiovascular Institute, at the Transcatheter Cardiovascular Therapeutics (TCT) conference.
- This study , simultaneously published in the Journal of the American College of Cardiology (JACC), leveraged egnite’s de-identified real-world database of over one million patients across 24 teaching and non-teaching United States health systems.
- Généreux and colleagues sought to unveil treatment patterns and outcomes associated with AS over 4 years.
- This study builds upon a robust body of medical research on the outcomes of patients with AS, highlighting the need for early identification and timely treatment of disease.
Health,
Medical Devices,
Technology,
Practice Management,
Software,
Artificial Intelligence,
Cardiology,
Partnership,
Prevalence,
Intervention,
Teaching,
Medical school,
Multimedia,
TVT,
CMO,
Assistant,
Medical University of South Carolina,
MD,
Patient,
Guideline,
TAVR,
Aortic regurgitation,
AR,
Aortic stenosis,
Medical imaging egnite, Inc. , a leading digital health company for cardiovascular care, and JenaValve Technology, Inc. , a developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, are pleased to announce a strategic partnership aimed to shed light on the care paradigm and associated outcomes of patients with aortic regurgitation (AR).
Key Points:
- egnite, Inc. , a leading digital health company for cardiovascular care, and JenaValve Technology, Inc. , a developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, are pleased to announce a strategic partnership aimed to shed light on the care paradigm and associated outcomes of patients with aortic regurgitation (AR).
- These findings also provide valuable insights for healthcare providers and policymakers, encouraging further attention toward improving outcomes for patients suffering from AR."
- Interventional cardiologist Dr. Nicholas S. Amoroso presented the first study from this partnership at TVT: The Structural Heart Summit.
- “The urgency for digital technologies to identify AR patients earlier and novel therapies to improve outcomes for this vulnerable patient population has never been greater.”
Technology,
Research,
Medical Devices,
Cardiology,
Software,
Practice Management,
Health,
Data Management,
Science,
Heart failure,
Survival,
Heart,
GDMT,
Heart Rhythm,
MD,
Patient,
Pharmaceutical industry,
Medical device “Over the last five years, new therapies to treat heart failure emerged with promising improvements in survival benefit. This study represents the first time we’ve seen an assessment of ‘5-class’ guideline-directed therapy -- up to 4 foundational medication classes plus ICD/CRT-D therapy -- for these patients,” said John Mignone, MD, Ph.D., Robert M. and Patricia Arnold Endowed Medical Director for Heart Failure and Co-Executive Medical Director, Swedish Heart and Vascular Institute. “The next big challenge to overcome is implementing care at a time of growing disease burden and fewer clinical resources. Artificial intelligence-powered insights, like those provided by egnite, will enable us to ensure appropriate care is provided to our entire patient population.”
Key Points:
- egnite, Inc. , a leading digital health company for cardiovascular care, announces today the release of novel research presented at Heart Rhythm 2023.
- Led by heart failure cardiologist John Mignone, the study utilized real-world data from egnite’s de-identified database of over 5.2 million cardiovascular patients from 20 leading heart programs across the United States.
- “Over the last five years, new therapies to treat heart failure emerged with promising improvements in survival benefit.
- “The next big challenge to overcome is implementing care at a time of growing disease burden and fewer clinical resources.
Retrieved on:
Wednesday, April 26, 2023
Surgery,
Medical Devices,
Health,
Health Technology,
Cardiology,
Stroke,
LAAC,
Health equity,
Ageing,
AF,
Bleeding,
Patient,
Physician,
Risk,
Atrial fibrillation,
Medical device egnite, Inc. , a leading digital health company for cardiovascular care, announces the expansion of its portfolio with the integration of a custom module designed to help physicians and health systems identify patients with atrial fibrillation (AF), deemed to be at elevated risk of stroke and bleeding, who are potentially eligible for left atrial appendage closure (LAAC) therapy.
Key Points:
- egnite, Inc. , a leading digital health company for cardiovascular care, announces the expansion of its portfolio with the integration of a custom module designed to help physicians and health systems identify patients with atrial fibrillation (AF), deemed to be at elevated risk of stroke and bleeding, who are potentially eligible for left atrial appendage closure (LAAC) therapy.
- This treatment is an alternative to blood thinners proven to reduce the risk of stroke in patients with non-valvular AF, a widespread condition among the aging population in the US.
- To date, the CardioCare platform has delivered:
“This expansion delivers a more streamlined and precise process for identifying and managing patients,” said Joel Portice, president and chief executive officer of egnite.
- “I look forward to seeing how this technology can help improve care for some of the most at-risk cardiovascular patients."
Retrieved on:
Wednesday, April 19, 2023
Technology,
Medical Devices,
Clinical Trials,
Cardiology,
Software,
Health,
General Health,
IOT (Internet of Things),
Data Management,
Heart,
Partnership,
Heart failure,
OH,
HF,
Clinical trial,
Multimedia,
Organization,
Patient,
Guideline,
AI,
Safety,
Pharmaceutical industry,
Medical device The partnership brings together the cutting-edge technology and expertise of both organizations with the goal of delivering innovative therapies to patients faster.
Key Points:
- The partnership brings together the cutting-edge technology and expertise of both organizations with the goal of delivering innovative therapies to patients faster.
- The Christ Health Network in Cincinnati, OH is the first site in Ancora Heart’s CORCINCH-HF trial to utilize egnite’s Trial Accelerator artificial intelligence (AI) technology to help identify eligible patients.
- The innovative solution can accelerate clinical trial enrollment through AI and big data processing, automatically screening hundreds of thousands of patients against trial parameters to help identify more trial candidates without hospital staff dedicating hours to manual chart review.
- “We believe this collaboration is a significant step forward for patients and are excited to be at the forefront of cardiovascular care.”
Alternative Medicine,
Health,
Medical Devices,
Technology,
Practice Management,
Software,
Cardiology,
Mortality,
Left ventricular hypertrophy,
Teaching,
Research,
Atrial fibrillation,
Patient,
Aortic stenosis,
Congress,
Abstract,
American College,
Presidential Commission of the Russian Federation to Counter Attempts to Falsify History to the Detriment of Russia's Interests,
Valvular heart disease,
Pulmonary hypertension,
Pharmaceutical industry,
Medical device egnite, Inc. , a leading digital health company for cardiovascular care, announces today two novel research studies were presented at the American College of Cardiology’s 72nd Annual Scientific Session Together with the World Congress of Cardiology (ACC.23/WCC) on March 5, 2023.
Key Points:
- egnite, Inc. , a leading digital health company for cardiovascular care, announces today two novel research studies were presented at the American College of Cardiology’s 72nd Annual Scientific Session Together with the World Congress of Cardiology (ACC.23/WCC) on March 5, 2023.
- The studies were led by renowned cardiologist Philippe Généreux and colleagues using egnite's extensive real-world database of over one million patients from 24 leading teaching and non-teaching institutions across the United States.
- The first study was recognized as one of the ACC’s top research abstracts in valvular heart disease in 2023.
- Corresponding two-year treatment rates for moderate-to-severe AS and severe AS were low, at 26.1% and 50.4% respectively
